과제정보
The authors received no financial support for the research, authorship, and/or publication of this article.
참고문헌
- Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019;53:1801913.
- Maron BA, Hess E, Maddox TM, et al. Association of borderline pulmonary hypertension with mortality and hospitalization in a large patient cohort: insights from the veterans affairs clinical assessment, reporting, and tracking program. Circulation 2016;133:1240-8.
- Ruopp NF, Cockrill BA. Diagnosis and treatment of pulmonary arterial hypertension: a review. JAMA 2022;327:1379-91.
- Galie N, Barbera JA, Frost AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 2015;373:834-44.
- D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343-9.
- Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL registry. Chest 2012;142:448-56.
- Jang AY, Lee H, Kim HC, Chung JW. Epidemiology of PAH in Korea: an analysis of the national health insurance data, 2002-2018. Korean Circ J 2023;53:313-27.
- Lim SS, Lee W, Kim YK, et al. The cumulative incidence and trends of rare diseases in South Korea: a nationwide study of the administrative data from the National Health Insurance Service database from 2011-2015. Orphanet J Rare Dis 2019;14:49.
- Lee JH, Hwang KK. End-of-life care for end-stage heart failure patients. Korean Circ J 2022;52:659-79.
- Oh S, Jung JH, Ahn KJ, et al. Stem cell and exosome therapy in pulmonary hypertension. Korean Circ J 2022;52:110-22.